Paragraph IV (Para IV) Patent Certification | Learn With FAQs

What Is a Paragraph IV Patent Certification?

A Paragraph IV (Para IV) Patent Certification is a legal declaration made by a generic drug manufacturer when filing an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act).

In a Paragraph IV filing, the generic applicant certifies that the brand-name drug’s listed patent is:

• Invalid,
• Unenforceable, or
• Not infringed by the proposed generic product.

This strategy allows a generic company to seek market entry before patent expiration, potentially gaining a significant competitive and financial advantage.

Related:

• What Is DMF (Drug Master File): Learn In 11 Minutes
• Regulatory Affairs

Types of Patent Certifications (ANDA Patent Certifications Explained)

When submitting an ANDA, applicants must make one of four patent certifications:

1. Paragraph I

No patent information is listed in the FDA’s Orange Book.

2. Paragraph II

The listed patent has already expired.

3. Paragraph III

The applicant agrees to wait until the patent expires before marketing the generic.

4. Paragraph IV

The patent is invalid, unenforceable, or will not be infringed by the generic product.

Among these, Paragraph IV certification is the most strategic and legally complex option, as it directly challenges the brand manufacturer’s patent rights.

Key Aspects of a Paragraph IV Filing

1. The “Act of Infringement”

Under U.S. patent law, filing a Paragraph IV certification is considered a technical act of patent infringement. This legal mechanism allows the brand-name company to immediately file a patent infringement lawsuit.

2. 45-Day Lawsuit Window & 30-Month Stay

Once notified of a Paragraph IV certification:

• The brand company has 45 days to file a lawsuit.
• If a lawsuit is filed within this window, the FDA automatically imposes a 30-month stay on final ANDA approval.
• The stay may end earlier if a court rules that the patent is invalid or not infringed.

This creates a structured litigation timeline under the Hatch-Waxman framework.

3. 180-Day Exclusivity (First-to-File Advantage)

The first generic applicant to submit a substantially complete ANDA with a Paragraph IV certification may receive:

180 days of exclusive generic marketing rights

During this exclusivity period:

• No other generic competitor can enter the market.
• The first filer can generate substantial revenue due to limited competition.

This exclusivity incentive drives aggressive patent challenges in the pharmaceutical industry.

Why Companies File Paragraph IV Certifications

The primary goal is:

• Early market entry
• Overcoming patent barriers
• Securing 180-day exclusivity
• Gaining significant commercial advantage

Paragraph IV filings are a critical component of pharmaceutical patent litigation strategy, generic drug competition, and lifecycle management.

Conclusion

A Paragraph IV Patent Certification is more than a regulatory formality — it is a powerful legal tool that enables generic manufacturers to challenge brand-name drug patents and potentially enter the market before patent expiry.

It plays a central role in:

• Hatch-Waxman litigation
• ANDA approval strategy
• Generic drug exclusivity
• Pharmaceutical patent disputes

FAQs

3. What are the four phases of FDA approval?

The four main phases of FDA drug approval are:

1. Preclinical Research – Laboratory and animal testing for safety.
2. Phase I Trials – Small group testing for safety and dosage.
3. Phase II Trials – Larger group testing for effectiveness and side effects.
4. Phase III Trials – Large-scale testing to confirm safety and efficacy before approval.

(After approval, Phase IV involves post-marketing surveillance.)

Further Reading:

Paragraph IV Patent Certifications